All Phenotypes Msh2<tm2.1Rak> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Msh2^tm2.1Rak
targeted mutation 2.1, Raju Kucherlapati
MGI:4460262

Summary

4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Msh2^tm2.1Rak/Msh2^tm2.1Rak	involves: 129/Sv * C57BL/6 * C57BL/6J * SJL	MGI:4460265
cn2	Msh2^tm1Rak/Msh2^tm2.1Rak Tg(Vil1-cre)20Syr/0	involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL	MGI:4460268
cn3	Msh2^tm2.1Rak/Msh2^tm3.1Rak Tg(Vil1-cre)20Syr/0	involves: 129/Sv * C57BL/6 * DBA/2 * SJL	MGI:4460267
cn4	Msh2^tm2.1Rak/Msh2^tm2.1Rak Tg(Vil1-cre)20Syr/0	involves: 129/Sv * C57BL/6 * FVB/N * SJL	MGI:4460266

Allelic Composition	Msh2^tm2.1Rak/Msh2^tm2.1Rak
Genetic Background	involves: 129/Sv * C57BL/6 * C57BL/6J * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2^tm2.1Rak mutation (1 available); any Msh2 mutation (95 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

neoplasm ( J:161577 )

N	• mice do not develop lymphomas

Allelic Composition	Msh2^tm1Rak/Msh2^tm2.1Rak Tg(Vil1-cre)20Syr/0
Genetic Background	involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2^tm1Rak mutation (1 available); any Msh2 mutation (95 available)
Msh2^tm2.1Rak mutation (1 available); any Msh2 mutation (95 available)
Tg(Vil1-cre)20Syr mutation (3 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased gastrointestinal tumor incidence ( J:161577 )

• beginning at 6 months, mice develop intestinal tumors

• by 10 months, 50% of mice develop intestinal tumors

increased intestinal adenocarcinoma incidence ( J:161577 )

• 82% of tumors

increased intestinal adenoma incidence ( J:161577 )

• 18% of tumors

abnormal tumor morphology ( J:161577 )

• mice develop fewer and larger tumors than in Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

• tumors do not respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

homeostasis/metabolism

abnormal mismatch repair ( J:161577 )

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

abnormal physiological response to xenobiotic ( J:161577 )

• tumors do not respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

• FOLFOX-treated intestinal mucosa exhibit decreased apoptosis compared with similarly treated cells from Msh2^tm2.1Wed homozygotes and Msh2^tm2.1Rak/Msh2^tm3.1Wed Tg(Vil-cre)20Syr mice

cellular

abnormal mismatch repair ( J:161577 )

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

digestive/alimentary system

increased gastrointestinal tumor incidence ( J:161577 )

• beginning at 6 months, mice develop intestinal tumors

• by 10 months, 50% of mice develop intestinal tumors

increased intestinal adenocarcinoma incidence ( J:161577 )

• 82% of tumors

increased intestinal adenoma incidence ( J:161577 )

• 18% of tumors

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Lynch syndrome		DOID:3883	OMIM:PS120435	J:161577

Allelic Composition	Msh2^tm2.1Rak/Msh2^tm3.1Rak Tg(Vil1-cre)20Syr/0
Genetic Background	involves: 129/Sv * C57BL/6 * DBA/2 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2^tm2.1Rak mutation (1 available); any Msh2 mutation (95 available)
Msh2^tm3.1Rak mutation (0 available); any Msh2 mutation (95 available)
Tg(Vil1-cre)20Syr mutation (3 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased gastrointestinal tumor incidence ( J:161577 )

• beginning at 10 months, mice develop intestinal tumors

• by 13 months, 50% of mice develop intestinal tumors

increased intestinal adenocarcinoma incidence ( J:161577 )

• 63% of tumors

increased intestinal adenoma incidence ( J:161577 )

• 37% of tumors

abnormal tumor morphology ( J:161577 )

• mice develop more and smaller tumors than in Msh2^tm1Rak/Msh2^tm2.1Wed Tg(Vil-cre)20Syr mice

• tumors respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2^tm1Rak/Msh2^tm2.1Wed Tg(Vil-cre)20Syr mice

homeostasis/metabolism

abnormal mismatch repair ( J:161577 )

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

abnormal physiological response to xenobiotic ( J:161577 )

• tumors respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2^tm1Rak/Msh2^tm2.1Wed Tg(Vil-cre)20Syr mice

• FOLFOX-treated intestinal mucosa cells exhibit decreased apoptosis compared with similarly treated cells from Msh2^tm2.1Wed homozygotes but increased compared with similarly treated cell from Msh2^tm1Rak/Msh2^tm2.1Wed Tg(Vil-cre)20Syr mice

cellular

abnormal mismatch repair ( J:161577 )

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

digestive/alimentary system

increased gastrointestinal tumor incidence ( J:161577 )

• beginning at 10 months, mice develop intestinal tumors

• by 13 months, 50% of mice develop intestinal tumors

increased intestinal adenocarcinoma incidence ( J:161577 )

• 63% of tumors

increased intestinal adenoma incidence ( J:161577 )

• 37% of tumors

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Lynch syndrome		DOID:3883	OMIM:PS120435	J:161577

Allelic Composition	Msh2^tm2.1Rak/Msh2^tm2.1Rak Tg(Vil1-cre)20Syr/0
Genetic Background	involves: 129/Sv * C57BL/6 * FVB/N * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2^tm2.1Rak mutation (1 available); any Msh2 mutation (95 available)
Tg(Vil1-cre)20Syr mutation (3 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:161577 )

• all mice die by 17 months of age

neoplasm

increased gastrointestinal tumor incidence ( J:161577 )

• 89% of mice develop small intestine tumors compared with 6% of wild-type mice

• 50% of small intestine tumors are adenomas while the rest are highly invasive adenocarcinomas

increased small intestine adenocarcinoma incidence ( J:161577 )

• 50% of small intestine tumors are highly invasive adenocarcinomas

increased intestinal adenoma incidence ( J:161577 )

• 50% of small intestine tumors are adenomas

increased lymphoma incidence ( J:161577 )

• in only 1 of 150 mice

homeostasis/metabolism

abnormal mismatch repair ( J:161577 )

• intestinal epithelial cells exhibit an increase in microsatellite instability compared with wild-type cells

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

cellular

abnormal mismatch repair ( J:161577 )

• intestinal epithelial cells exhibit an increase in microsatellite instability compared with wild-type cells

• tumor cells exhibit increased microsatellite instability compared with wild-type cells

digestive/alimentary system

increased gastrointestinal tumor incidence ( J:161577 )

• 89% of mice develop small intestine tumors compared with 6% of wild-type mice

• 50% of small intestine tumors are adenomas while the rest are highly invasive adenocarcinomas

increased small intestine adenocarcinoma incidence ( J:161577 )

• 50% of small intestine tumors are highly invasive adenocarcinomas

increased intestinal adenoma incidence ( J:161577 )

• 50% of small intestine tumors are adenomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Lynch syndrome		DOID:3883	OMIM:PS120435	J:161577

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/30/2024 MGI 6.23